Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat ...

In trading on Thursday, shares of Novartis (Symbol: NVS) crossed below their 200 day moving average of $85.90, changing hands as low as $85.60 per share. Novartis shares are currently trading off ...

Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Novartis (Symbol: NVS) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of ...

The Novartis logo is seen on a new cell and gene therapy factory in Stein, Switzerland. (File photo by Arnd Wiegmann/Reuters) Swiss pharmaceutical giant Novartis announced it will spend $23 ...

Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.

Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants.